Decompensated Liver Cirrhosis
12
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
TIPS in Patients With Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
LEOPARD Training and Validation Data Collection Study
LEOPARD Prospective Validation Cohort 1
An Follow-Up Study of Liver Cirrhosis
Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis
A Study of ADR-001 in Patients With Liver Cirrhosis
Effect of Mesenchymal Stem Cells-derived Exosomes in Decompensated Liver Cirrhosis
Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis